Get the Stockscreener App
555.91
1.60%
8.76
After Hours:
555.91
United Therapeutics Corp stock is traded at $555.91, with a volume of 531.99K.
It is up +1.60% in the last 24 hours and up +2.94% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$547.15
Open:
$554.941
24h Volume:
531.99K
Relative Volume:
1.06
Market Cap:
$23.60B
Revenue:
$3.17B
Net Income/Loss:
$1.29B
P/E Ratio:
20.52
EPS:
27.0947
Net Cash Flow:
$1.01B
1W Performance:
+2.30%
1M Performance:
+2.94%
6M Performance:
+11.92%
1Y Performance:
+88.30%
1-Day Range:
$547.62
$558.59
1-Week Range:
$535.44
$558.59
52-Week Range:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
555.91 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.77 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.82 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.64 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.80 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026 - Yahoo Finance
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 30 June By Investing.com - Investing.com Canada
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock - Investing.com
Big Pharma Has a Case of Merger Mania - The Motley Fool
United Therapeutics Corporation 8-K Filing Details: Stock Incentive Plan, Key Shareholder Info & SEC Compliance (June 2026) – Minichart - Minichart
FDA approves United Therapeutics’ LungFX lung perfusion device By Investing.com - Investing.com South Africa
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs - Benzinga
United Therapeutics (UTHR) Secures FDA Approval for LungFX - GuruFocus
United Therapeutics (UTHR) Receives FDA Approval for LungFX Devi - GuruFocus
FDA approves United Therapeutics’ LungFX lung perfusion device - Investing.com
FDA approves United Therapeutics' LungFX to assess donor lungs - Stock Titan
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation For: 26 June By Investing.com - Investing.com Canada
United Therapeutics Corp Annual Shareholders Meeting Transcript - GuruFocus
Martine A. Rothblatt sells $5.2m United Therapeutics shares - Investing.com UK
Martine A. Rothblatt sells $5.2m United Therapeutics shares By Investing.com - Investing.com Australia
Form 4 United Therapeutics Corporation For: 25 June By Investing.com - Investing.com Nigeria
United Therapeutics chairperson & CEO sells $5.17m in stock - Investing.com UK
United Therapeutics chairperson & CEO sells $5.17m in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $5.1m in UTHR shares By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 24 June By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $5.1m in UTHR shares - Investing.com
United Therapeutics - Forbes
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock By Investing.com - Investing.com Australia
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock - Investing.com UK
Form 4 United Therapeutics Corporation For: 22 June By Investing.com - Investing.com Australia
United Therapeutics Corp (UTHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks - StockStory
United Therapeutics EVP Mahon sells $4.5m in company stock - Investing.com UK
United Therapeutics EVP Mahon sells $4.5m in company stock By Investing.com - Investing.com South Africa
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 02 '26 |
Sale |
554.61 |
9,500 |
5,268,781 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 02 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 02 '26 |
Sale |
552.56 |
8,300 |
4,586,275 |
45,172 |
3.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):